In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment.1
After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities.
In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer.
NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.
A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.
If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.
In 2004, doctors told my husband Mike there was nothing more they could do—the pancreatic cancer he was diagnosed with would soon take his life.
A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?
A recent article in JAMA Network Open published by myself and my research collaborators—Jill Harrison at Brown University, Sarah Yarborough at Fred Hutch, and Tammy Stokes at Maury Regional Medical Center—examined the potential for a brief communication-based intervention to help older adults with cancer who live in rural settings better manage their pain.
A study recently published in JAMA sheds light on cancer risks associated with carrying germline CDH1 mutations, challenging previous, potentially inflated, lifetime cancer risk estimates.
